Imaging of the dopaminergic system in parkinsonism with spet

Nuclear Medicine Communications

Volumn 22, Issue 7, 2001, Pages 819-827

  Tatsch, K ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Dopamine D2 like receptors; Dopamine transporter; Parkinsonism; Single photon emission tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER;

CONFERENCE PAPER; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOPAMINERGIC SYSTEM; HUMAN; IMAGE ANALYSIS; IMAGING; METHODOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DISEASE PROGRESSION; DOPAMINE; HUMANS; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034952649     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200107000-00015     Document Type: Review

References (81)

1. Brooks DJ. Advances in imaging Parkinson’s disease. Curr Opin Neurol 1997; 10: 327-331.
2. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26: 171-182.
3. Innis RB. Single photon emission computed tomography imaging of dopaminergic function: presynaptic transporter, postsynaptic receptor, and ‘intrasynaptic’ transmitter. Adv Pharmacol 1998; 42: 215-219.
4. 123I]2β-carboxymethoxy-3β-(4-iodophenyl)tropane (β-CIT): high affinity SPECT radiotracer of monoamine re-uptake sites in brain. J Med Chem 1991; 34: 3144-3146.
5. Kung MP, Essman WD, Frederick D et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 1995; 20: 316-324.
6. Neumeyer JL, Wang S, Gao Y et al. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994; 37: 558-561.
7. Guilloteau D, Emond P, Baulieu JL et al. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4′-m ethylphenyl)nortropane (PE2I). Nucl Med Biol 1998; 25: 331-337.
8. 99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997; 24: 372-380.
9. 123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 1989; 30: 88-92.
10. Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. J Nucl Med 1990; 31: 648-654.
11. 125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 1991; 49: 617-628.
12. 123I-labeled 2′-iodospiperone and imaging of D2 dopamine receptors in the human brain using SPECT. Int J Rad Appl Instrum B 1992; 19: 523-529.
13. Chabriat H, Levasseur M, Vidailhet M et al. In-vivo SPECT imaging of D2 receptor with iodine-iodolisuride: results in supranuclear palsy. J Nucl Med 1992; 33: 1481-1485.
14. Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 1999; 40: 1091-1097.
15. 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 2000; 41: 220-227.
16. Acton PD, Pilowsky LS, Kung HF, Ell PJ. Automatic segmentation of dynamic neuroreceptor single-photon emission tomography images using fuzzy clustering. Eur J Nucl Med 1999; 26: 581-590.
17. Acton PD, Mozley PD, Kung HF. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson’s disease. Eur J Nucl Med 1999; 26: 1413-1423.
18. 123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm 1998; 105: 1213-1228.
19. 123I]-FP-CIT study group. Mov Disord 2000; 15: 503-510.
20. 123I]β-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord 1997; 12: 448-451.
21. 123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998; 43: 792-800.
22. 123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997; 50: 9-24.
23. Brücke T, Podreka I, Angelberger P et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metabol 1991; 11: 220-228.
24. 123I-IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun 1991; 12: 699-707.
25. Laulumaa V, Kuikka JT, Soininen H, Bergström K, Länsimies E, Riekkinen P. Imaging of D2 dopamine receptors of patients with Parkinson’s disease using single photon emission computed tomography and iodobenzamide I-123. Arch Neurol 1993; 50: 509-512.
26. 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun 1994; 15: 806-813.
27. Knable MB, Jones DW, Coppola R et al. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinsons’s disease. J Nucl Med 1995; 36: 1216-1225.
28. Hertel A, Weppner M, Baas H et al. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy. Nucl Med Commun 1997; 18: 811-822.
29. 123I-IBZM single photon emission computed tomography. Arch Neurol 1993; 50: 513-516.
30. Brücke T, Wenger S, Asenbaum S et al. Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol 1993; 60: 494-500.
31. 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047-1056.
32. Buck A, Westera G, Sutter M, Albani C, Kung HF, von Schulthess GK. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J Nucl Med 1995; 36: 1196-1200.
33. Yonekura Y, Saji H, Iwasaki Y et al. Initial clinical experiences with dopamine D2 receptor imaging by means of 2′-iodospiperone and single-photon emission computed tomography. Ann Nucl Med 1995; 9: 131-136.
34. Cordes M, Hierholzer J, Schelosky L et al. Iodine-123-iodo-lisuride SPECT in Parkinson’s disease. J Nucl Med 1996; 37: 22-25.
35. 123I-iodolisuride SPET. Nucl Med Commun 1999; 20: 77-84.
36. Pirker W, Asenbaum S, Wenger S et al. Iodine-123-epidepride-SPECT: studies in Parkinson’s disease, multiple system atrophy and Huntington’s disease. J Nucl Med 1997; 38: 1711-1717.
37. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with ‘de novo’ parkinsonism. Neurology 1992; 42: 556-561.
38. Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W. Correlation of clinical response in apomorphine test with D2 receptor status as demonstrated by IBZM-SPECT. Mov Disord 1993; 8: 453-458.
39. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993; 43(suppl 6): S17-20.
40. 123I]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord 1997; 12: 898-902.
41. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13: 16-19.
42. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
43. 123I]IBZM SPECT studies in Parkinsonism: diagnostic performance of a 3-D automated evaluation program. J Nucl Med 2000; 41: 217p
44. Ichise M, Kim YJ, Ballinger JR et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 1999; 52: 1206-1214.
45. 123I-IBZM-SPECT scanning in levodopa naive Parkinson’s disease. Mov Disord 1998; 13: 438-445.
46. 123I]IBF and β-CIT SPECT. J Nucl Med 1998; 39: 14p
47. Tatsch K, Kerner M, Linke R, Schwarz J, Mozley PD, Hahn K. Combined evaluation of the pre- and postsynaptic dopaminergic system for improved discrimination between idiopathic and non-idiopathic Parkinsonian syndromes. J Nucl Med 1998; 39: 124p
48. Dresel SH, Kung MP, Huang XF et al. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons. J Nucl Med 1999; 40: 660-666.
49. Innis RB, Seibyl JP, Scanley BE et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson’s disease. Proc Natl Acad Sci USA 1993; 90: 11965-11969.
50. 123I]β-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 1993; 94: 137-146.
51. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 62: 133-140.
52. Tatsch K, Schwarz J, Mozley PD et al. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [I-123]IPT and SPECT. Eur J Nucl Med 1997; 24: 415-421.
53. 99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med 2000; 41: 584-589.
54. 123I]-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996; 46: 231-237.
55. Schwarz J, Linke R, Kerner M et al. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson’s disease: implications for a preclinical diagnosis. Arch Neurol 2000; 57: 205-208.
56. Tissingh G, Booij J, Bergmans P et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J Nucl Med 1998; 39: 1143-1148.
57. 18F-dopa PET study. Ann Neurol 1997; 41: 222-229.
58. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 1995; 38: 589-598.
59. Asenbaum S, Brücke T, Pirker W et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson’s disease. J Nucl Med 1997; 38: 1-6.
60. Rinne JO, Kuikka JT, Bergström KA et al. Striatal dopamine transporter in different disability stages of Parkinson’s disease. Parkinsonism Related Disord 1995; 1: 47-51.
61. van Dyck CH, Seibyl JP, Malison RT et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nucl Med 1995; 36: 1175-1181.
62. Mozley PD, Kim HJ, Gur RC et al. Iodine-123-IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. J Nucl Med 1996; 37: 1965-1970.
63. Mozley PD, Acton PD, Barraclough ED et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med 1999; 40: 1812-1817.
64. 123I-β-CIT: assessment of progression in Parkinson’s disease. Neurology 1997; 48(suppl): A207-208
65. Booij J, Winogrodzka A, Bergmans P, Wolters EC, Stoof JC, Royen EA. [I-123]β-CIT and [I-123]FP-CIT SPECT are useful methods to monitor progression of dopaminergic degeneration in early-stage Parkinson’s disease. J Nucl Med 1999; 40: 28P
66. Seibyl JP, Innis RB, Early ML, Fussell BA, Marek K. Baseline striatal dopamine transporter uptake measured with [I-123]β-CIT SPECT may predict rate of disease progression in idiopathic Parkinson’s disease. J Nucl Med 1999; 40: 27P
67. Kerner M, Tatsch K, Linke R et al. Monitoring the intraindividual progression of Parkinson’s disease with [I-123]IPT and SPECT. J Nucl Med 1998; 39: 14P
68. 18F-dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 1996; 119: 585-591.
69. 18F]CFT. Ann Neurol 2000; 47: 804-808.
70. Seibyl JP, Marek K, Sheff K et al. Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson’s patients. J Nucl Med 1997; 38: 1453-1459.
71. Linke R, Gostomzyk J, Hahn K, Tatsch K. [I-123]IPT-binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 2000; 27: 1809-1812.
72. Hierholzer J, Cordes M, Venz S et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med 1998; 39: 954-960.
73. Stoof JC, Winogrodzka A, van Muiswinkel FL et al. Leads for the development of neuroprotective treatment in Parkinson’s disease and brain imaging methods for estimating treatment efficacy. Eur J Pharmacol 1999; 375: 75-86.
74. Shoulson I. Where do we stand on neuroprotection? Where do we go from here? Mov Disord 1998; 13(suppl 1): 46-48.
75. 123I]β-CIT. Mov Disord 1999; 14: 436-442.
76. Ahlskog JE, Uitti RJ, O’Connor MK et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson’s disease. Mov Disord 1999; 14: 940-946.
77. 123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med 2000; 27: 346-349.
78. Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-dopa. J Nucl Med 1996; 37: 1112-1115.
79. 123Jod-IBZM-SPECT bei Patienten mit Morbus Parkinson. Fortschr Röntgenstr 1992; 157: 390-398.
80. Scherer J, Tatsch K, Schwarz J, Oertel W, Kirsch MC, Albus M. Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psychiatry 1994; 36: 627-629.
81. Brücke T, Wober C, Podreka I et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 1995; 15: 513-518.